Skip to content

Daniel Margolis


New York

Daniel Margolis
Daniel Margolis


New York

Dan is a partner in the Intellectual Property practice. Clients rely upon the combination of legal and scientific expertise he brings to his practice, which focuses on patent litigation and strategic counselling, with a particular emphasis on pharmaceuticals and chemical technologies. His expertise allows him to address complex issues for his clients with respect to legal and overall business strategies.

Dan has litigated patent disputes extensively on behalf of both plaintiffs and defendants in federal courts, before the Patent Trial and Appeal Board, and in the International Trade Commission. His cases predominantly involve highly complex chemical technologies, whether in the context of Hatch-Waxman or BPCIA cases or those involving traditional allegations of infringement of chemical patents.

Related articles

DNA strand blue background

News: 25 February 2022

Allen & Overy expanding life sciences intellectual property litigation practice with five new U.S. partners and launching in Boston

A&O today announced that Elizabeth Holland, Bill James, John Bennett, Nick Mitrokostas and Daniel Margolis will join as partners in A&O’s U.S. Intellectual Property (IP) Litigation practice, focused…

Read more

Experience highlights



Intellectual Property


Life Sciences


New York

1221 Avenue of the Americas
New York
NY 10020

View office →



Admitted to the Bar of the State of New York

U.S. District Court for the Southern District of New York

U.S. District Court for the Northern District of New York


J.D., New York University School of Law, 2006

Ph.D., Chemical Engineering, Carnegie Mellon University, 2003

B.S., Chemical Engineering, Rutgers University, 1998

Other noteworthy experience


  • Teva representation in a patent infringement litigation against multiple generic defendants involving patents directed to a process for manufacturing glatiramer acetate (Copaxone®). [In re: Copaxone 775 Patent Litigation (D. Del.)]
  • Teva Pharmaceuticals and Yeda Research and Development representation in the trial of consolidated cases in the District of Delaware relating to Teva’s 40mg three times weekly Copaxone product.
  • Enzymotec representation in a United States International Trade Commission investigation concerning alleged infringement by Enzymotec’s krill oil supplements. The representation also involved an inter partes review before the Patent Trial and Appeal Board in the United States Patent and Trademark Office. [In the Matter of Certain Omega-3 Extracts from Marine or Aquatic Biomass and Products Containing the Same (ITC).]*
  • Globally Diversified Conglomerate conducting IP due diligence regarding freedom to operate and scope and strength of patent protection.
  • Biotechnology Company provided freedom to operate analysis.

*Experience prior to joining Allen & Overy.